© Copyright 2021 Synerphysics, Inc. All rights reserved. Dillon Capital Strategies is an operating unit of SynerPhysics, Inc.
Joseph S. Dillon, PH.D., MBA
President, Dillon Capital Strategies
Joseph S. Dillon, Ph.D., MBA, is President & CEO of
SynerPhysics, Inc. and President of Dillon Capital
Strategies, the strategy and business analytics advisory
arm of SynerPhysics. Dr. Dillon is a seasoned
pharmaceutical executive with over 30 years of
experience. He has extensive experience in global
pharmaceutical business development, planning and
analysis, corporate finance, M&A, licensing, and
technology valuations. Dr. Dillon has screened
thousands of opportunities, valued over 400 deals and
has been involved in over 45 closed transactions over
the course of his career. Since forming Dillon Capital Strategies, Dr. Dillon has consulted
dozens of companies and held interim senior positions, including CEO and CFO at select
clients. Dr. Dillon also provides specialized, strategic and transaction focused training for
biopharma professionals. Prior to this, Dr. Dillon held senior positions in pharmaceutical
management consulting firms, most significantly as Senior Vice President, Head of
Corporate Development Services and Valuations for The Mattson Jack Group (now
KantarHealth). Other previous positions include CEO, President, and Director of The
Pharmaceutical Development Center (sold to AAI), a pharmaceutical developer and
manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding
company (IPO, then sold to US Bancorp); CFO and Treasurer of Oread Inc., a contract
pharmaceutical developer and manufacturer; and corporate positions with predecessor
companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life
Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent
industry organization events. Dr. Dillon holds a Ph.D. in Theoretical Physics, an M.B.A. in
International Finance and a bachelor’s degree in Finance.